NCT01794078View on ClinicalTrials.gov

A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions

Acute Mountain Sickness and Fatigue

Interventions

DRUG

Aminophylline 400 mg

Xanthine derivative

DRUG

Ambrisentan 5 mg

Endothelin receptor antagonist

OTHER

Placebo

Trial Locations (2)

27710

Duke Center for Hyperbaric Medicine, Durham

Duke Clinical Research Unit (DCRU), Durham

All Listed Sponsors

collaborator

United States Department of Defense

FED

lead

Robert J Noveck, M.D.

OTHER

NCT01794078 - A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude | Biotech Hunter | Biotech Hunter